Presspart Manufacturing Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Presspart Manufacturing Limited - overview
Established
1970
Location
-, -, UK
Primary Industry
Medical Devices & Equipment
About
Presspart Manufacturing Limited specializes in the production of drug delivery devices, focusing on Metered-Dose Inhalers (MDIs) and Dry Powder Inhalers (DPIs) to enhance effective medication delivery for respiratory patients. Presspart Manufacturing Limited, founded in 1970, operates primarily in the UK and specializes in manufacturing drug delivery solutions. In 2002, the company was acquired by Heitkamp & Thurmann KG and rebranded as H&T Presspart. The company has a global presence with operations across Europe, North America, and Asia, serving a diverse clientele in the pharmaceutical sector.
H&T Presspart specializes in the manufacturing of drug delivery devices and pharmaceutical components. Its primary products include Metered-Dose Inhalers (MDIs) and Dry Powder Inhalers (DPIs), designed to enhance drug delivery efficiency. The company collaborates with leading pharmaceutical firms, providing essential components for their products, leveraging over 50 years of industry experience. In 2023, H&T Presspart reported a revenue of USD 60.
90 mn and an EBITDA of USD 17. 19 mn, primarily generated through B2B transactions with pharmaceutical companies. Revenue is derived from long-term contracts and volume-based pricing models for their flagship products, including the Vytal® RTU snap-fit closure technology. H&T Presspart's strategy for future growth includes the design and launch of new drug delivery products, with exact release dates to be confirmed.
The company aims to expand into additional markets in Asia and North America by 2025. Recent funding, raised during the acquisition in 2002, will support these initiatives by enhancing manufacturing capabilities and product development.
Primary Industry
Medical Devices & Equipment
Sub Industries
Medical Supplies, Specialty Pharmaceuticals
Website
www.presspart.com
Verticals
Manufacturing
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Presspart Manufacturing Limited - timeline of key events
Presspart Manufacturing Limited - financials
| Fiscal Year Ended | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 21,855,000 | 28,261,000 | 25,578,000 | 25,192,000 | 26,451,000 | 28,230,000 | 28,218,000 | 33,218,000 | 35,884,000 | 36,996,000 | 37,440,000 | - | - | - |
| % Revenue Growth (YoY) | - | 29.3% | (9.5%) | (1.5%) | 5.0% | 6.7% | (0.0%) | 17.7% | 8.0% | 3.1% | 1.2% | - | - | - |
| EBITDA (USD) | 3,717,000 | 4,906,000 | 4,307,000 | 4,040,000 | 4,833,000 | 4,915,000 | 5,585,000 | 7,471,000 | 8,301,000 | 8,017,000 | 8,614,000 | - | - | - |
| Operating Income (USD) | 2,680,000 | 3,929,000 | 3,205,000 | 2,813,000 | 3,517,000 | 3,399,000 | 3,667,000 | 5,255,000 | 6,043,000 | 5,503,000 | 5,929,000 | - | - | - |
| Operating Margin | 12.3% | 13.9% | 12.5% | 11.2% | 13.3% | 12.0% | 13.0% | 15.8% | 16.8% | 14.9% | 15.8% | - | - | - |
| % EBITDA Margin | 17.0% | 17.4% | 16.8% | 16.0% | 18.3% | 17.4% | 19.8% | 22.5% | 23.1% | 21.7% | 23.0% | - | - | - |
| NET Income (USD) | 1,892,000 | 2,872,000 | 2,387,000 | 2,120,000 | 2,645,000 | 2,483,000 | 2,939,000 | 4,093,000 | 4,865,000 | 4,102,000 | 4,464,000 | - | - | - |
| % Net Margin | 8.7% | 10.2% | 9.3% | 8.4% | 10.0% | 8.8% | 10.4% | 12.3% | 13.6% | 11.1% | 11.9% | - | - | - |
Presspart Manufacturing Limited - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | Novelex AG | - | ||||||||
| Trade Sale | Completed | Presspart Manufacturing Limited | - | ||||||||
| Buyout | Completed | Presspart Manufacturing Limited | - |
Displaying 1 - 3 of 3
Presspart Manufacturing Limited - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.